TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15114906

Group type: EXPERIMENTAL
Intervention: Placing the encoding question after the target stimulus in explicit memory tasks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard shallow encoding tasks
Number of subjects: 0
Study: 10789325

Group type: EXPERIMENTAL
Intervention: Experimental group (n = 36) underwent four, monthly 25% drug reduction stages
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (n = 20) with no planned drug changes
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Experimental group (n = 36) undergoing drug reduction
Number of subjects: 56
Study: 9149200

Group type: EXPERIMENTAL
Intervention: ANP infusion (2, 4, and 6 pmol/kg.min for 15 min each)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (three periods of 15 min each)
Number of subjects: 8
Study: 8397837

Group type: EXPERIMENTAL
Intervention: Colgate Precision Full Head soft toothbrush
Number of subjects: 75

Group type: COMPARATOR
Intervention: Oral-B 40 toothbrush
Number of subjects: 75

Group type: COMPARATOR
Intervention: Reach Full-Head soft toothbrush
Number of subjects: 75
Study: 3093667

Group type: EXPERIMENTAL
Intervention: Nitro-Dur
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nitro-Dur II
Number of subjects: 24
Study: 30946077

Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair with Inferior Mesenteric Artery (IMA) Embolization
Number of subjects: 106

Group type: COMPARATOR
Intervention: Endovascular Aneurysm Repair without IMA Embolization (Control)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair with IMA Embolization
Number of subjects: 106
Study: 31161361

Group type: EXPERIMENTAL
Intervention: Local desmopressin (10 μg) administered as a single puff in each side of the nasal cavity 30 minutes before surgery
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Local desmopressin
Number of subjects: 90
Study: 29624269

Group type: EXPERIMENTAL
Intervention: 0.5% Cladophora SFE extract in emulsion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo emulsion
Number of subjects: 0
Study: 26979520

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice daily in combination with dipyridamole slow-release 200 mg twice daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Metformin 500 mg twice daily alone
Number of subjects: 18
Study: 24016684

Group type: EXPERIMENTAL
Intervention: Almitrine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22344611

Group type: EXPERIMENTAL
Intervention: DST (automated decision support tool)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: DVD (educational DVD)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: DST+DVD (both DST and educational DVD)
Number of subjects: 288

Group type: COMPARATOR
Intervention: STG (structured SMBG alone)
Number of subjects: 288
Study: 19960983

Group type: EXPERIMENTAL
Intervention: Renshen Jianxin Capsule (RJC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Metformin (Control)
Number of subjects: 80
Study: 17307761

Group type: EXPERIMENTAL
Intervention: Supervised 12 week group exercise programme
Number of subjects: 203

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 203
Study: 15289797

Group type: EXPERIMENTAL
Intervention: Rivastigmine 6-12 mg/day
Number of subjects: 367

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 367
Study: 11135086

Group type: EXPERIMENTAL
Intervention: L-folinic acid (FNA) 20 mg/day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Folic acid (FA) 15 mg/day
Number of subjects: 48
Study: 9853274

Group type: EXPERIMENTAL
Intervention: valsartan 80 mg o.d.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: enalapril 20 mg o.d.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: valsartan 80 mg o.d. + indomethacin 50 mg bid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: enalapril 20 mg o.d. + indomethacin 50 mg bid
Number of subjects: 20
Study: 8037389

Group type: EXPERIMENTAL
Intervention: Prochlorperazine 25 mg rectal suppository
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3182519

Group type: EXPERIMENTAL
Intervention: CHO (Carbohydrate ingestion)
Number of subjects: 5

Group type: COMPARATOR
Intervention: CON (Sweet placebo)
Number of subjects: 5
Study: 31852749

Group type: EXPERIMENTAL
Intervention: 2×10^6/kg BM-MNC injection
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 5×10^6/kg BM-MNC injection
Number of subjects: 24

Group type: COMPARATOR
Intervention: BM-MNC non-treated (Control)
Number of subjects: 24
Study: 29660034

Group type: EXPERIMENTAL
Intervention: E-cigarettes (Arm 1)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Placebo e-cigarettes (Arm 2)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (Arm 3)
Number of subjects: 210
Study: 28486474

Group type: EXPERIMENTAL
Intervention: Genetically lowered 25-hydroxyvitamin D (25OHD) levels
Number of subjects: 146761
Study: 25408331

Group type: EXPERIMENTAL
Intervention: Serelaxin 10 µg/kg/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Serelaxin 30 µg/kg/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Serelaxin 100 µg/kg/day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Serelaxin 30 µg/kg/day (Caucasian cohort)
Number of subjects: 32
Study: 23278466

Group type: EXPERIMENTAL
Intervention: Vasoconstrictor (somatostatin or terlipressin infusion)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Proton Pump Inhibitor (omeprazole or pantoprazole infusion)
Number of subjects: 118
Study: 20541832

Group type: EXPERIMENTAL
Intervention: Twice daily training plus usual care
Number of subjects: 53

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Both groups (intervention and control)
Number of subjects: 53
Study: 19471252

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) maintenance therapy
Number of subjects: 425

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 425
Study: 17461851

Group type: EXPERIMENTAL
Intervention: TMC114/ritonavir (TMC114/r) 600/100 mg twice a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control protease inhibitor (CPI)
Number of subjects: 0
Study: 15141519

Group type: EXPERIMENTAL
Intervention: Intrapartum antibiotic prophylaxis with Penicillin G or Clindamycin for GBS carriers (161 out of 754 newborns, 21.4%)
Number of subjects: 3023

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 3023
Study: 15187512

Group type: EXPERIMENTAL
Intervention: h‐ANP (50 ng.kg(‐1).min(‐1))
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 11097098

Group type: EXPERIMENTAL
Intervention: Extended Information Routine (EIR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard information from the specialist clinics
Number of subjects: 20
Study: 9350301

Group type: EXPERIMENTAL
Intervention: MKP culture
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: PCR
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: BSK II culture
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: All methods combined
Number of subjects: 758
Study: 1440744

Group type: EXPERIMENTAL
Intervention: Intensive intervention (18 therapy appointments over one year, including one home visit)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 126
Study: 3770386

Group type: EXPERIMENTAL
Intervention: Viscous lidocaine gargle (2%) diluted with tap water (39 ml + 15 ml)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: COMPARATOR
Intervention: No treatment (neither viscous lidocaine nor placebo)
Number of subjects: 90
Study: 31081373

Group type: EXPERIMENTAL
Intervention: Swimming training program for 8 weeks
Number of subjects: 33
Study: 30337746

Group type: EXPERIMENTAL
Intervention: Group D1 (10 mL of 0.375% ropivacaine + dexmedetomidine 0.2 μg/(kg×h))
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group D2 (10 mL of 0.375% ropivacaine + dexmedetomidine 0.7 μg/(kg×h))
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group R (10 mL of 0.375% ropivacaine)
Number of subjects: 90
Study: 27588959

Group type: EXPERIMENTAL
Intervention: UFT/LV (uracil‐tegafur and leucovorin)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: UFT/LV
Number of subjects: 180
Study: 25084042

Group type: EXPERIMENTAL
Intervention: Anodal over the right with cathodal over the left DLPFC
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cathodal over the right with anodal over the left DLPFC
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Right cathodal/left cathodal DLPFC
Number of subjects: 13
Study: 24446539

Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control (Aripiprazole and Ziprasidone)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control (Paliperidone and Ziprasidone)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control (Paliperidone and Aripiprazole)
Number of subjects: 254
Study: 20691837

Group type: EXPERIMENTAL
Intervention: Hospital readmission or death at 30 days
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Hospital readmission or death at 90 days
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Reasons for hospitalization at 30 days
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Predictors of readmission or death at 30 days
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Predictors of readmission or death at 90 days
Number of subjects: 614
Study: 18292286

Group type: EXPERIMENTAL
Intervention: CHOP-like regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Intensive regimen
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Mediastinal lymphadenopathy
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Increase in large cells and high level of CD10 and CXCL13
Number of subjects: 157
Study: 15781679

Group type: EXPERIMENTAL
Intervention: UV facial photograph and photoaging information
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: UV facial photograph and photoaging information plus sunless tanning lotion
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 146
Study: 12634948

Group type: EXPERIMENTAL
Intervention: Urate oxidase prophylaxis (period 3)
Number of subjects: 1791

Group type: COMPARATOR
Intervention: No urate oxidase (period 1)
Number of subjects: 1791

Group type: EXPERIMENTAL
Intervention: Urate oxidase therapeutic use (period 2)
Number of subjects: 1791

Group type: EXPERIMENTAL
Intervention: B‐ALL (period 3)
Number of subjects: 1791
Study: 10505829

Group type: EXPERIMENTAL
Intervention: Automated digital imaging with objective, automated, computerized image analysis
Number of subjects: 206

Group type: COMPARATOR
Intervention: Masked review of a complete pediatric ophthalmic exam
Number of subjects: 206
Study: 8734859

Group type: EXPERIMENTAL
Intervention: IV adenosine-triphosphate (ATP) 10 or 20mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: IV verapamil up to 15mg
Number of subjects: 50
Study: 1882903

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 7116051

Group type: EXPERIMENTAL
Intervention: Social intervention (education about schizophrenia, group for relatives, family sessions for relatives and patients)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Routine out‐patient care (Control group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Social intervention
Number of subjects: 24
Study: 31119418

Group type: EXPERIMENTAL
Intervention: Integrated reading of PET/CT and MRI
Number of subjects: 201
Study: 28864226

Group type: EXPERIMENTAL
Intervention: CDDP with Mg (2.5mg/kg CDDP, 40mg/kg MgSO4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CDDP with Mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: CDDP alone
Number of subjects: 0
Study: 25796986

Group type: EXPERIMENTAL
Intervention: IR/ER HB/APAP
Number of subjects: 403

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study: 23314670

Group type: EXPERIMENTAL
Intervention: Bifidobacterium infantis natren life start strain super strain (Lifestart 2) (2×10(9) colony‐forming units per capsule) for 3 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 22
Study: 20858149

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg three times a day)
Number of subjects: 539

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 539
Study: 19947443

Group type: EXPERIMENTAL
Intervention: Strontium ranelate, a first-line agent for the treatment of postmenopausal osteoporosis.
Number of subjects: 3
Study: 17123867

Group type: EXPERIMENTAL
Intervention: Melatonin (intravenous administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15170026

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg twice a day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 16
Study: 11785999

Group type: EXPERIMENTAL
Intervention: Tissue Doppler technique measuring myocardial velocities at four left ventricular sites (anterior, left, posterior, septal) and three levels (basal, mid-cavity, apical).
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tissue Doppler technique measuring myocardial velocities.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tissue Doppler technique measuring diastolic pulmonary venous flow velocity.
Number of subjects: 60
Study: 9433336

Group type: EXPERIMENTAL
Intervention: Paroxetine 40 mg/day
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/day
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Paroxetine 10 mg/day
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study: 7663801

Group type: COMPARATOR
Intervention: L-NMMA (490 mg by inhalation)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Prednisolone (30 mg orally for 3 days)
Number of subjects: 38
Study: 2698244

Group type: EXPERIMENTAL
Intervention: 0.5 mg pindolol
Number of subjects: 46

Group type: COMPARATOR
Intervention: 3 mg propranolol
Number of subjects: 46
Study: 769287

Group type: EXPERIMENTAL
Intervention: Sulfacytine (1Gm. per day)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Sulfisoxazole (4Gm. per day)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Sulfacytine
Number of subjects: 132

Group type: COMPARATOR
Intervention: Sulfisoxazole
Number of subjects: 132
Study: 6264506

Group type: EXPERIMENTAL
Intervention: 0.243% sodium fluoride-silica abrasive dentifrice
Number of subjects: 3093

Group type: COMPARATOR
Intervention: 0.4% stannous fluoride-calcium pyrophosphate dentifrice
Number of subjects: 3093

Group type: COMPARATOR
Intervention: Nonfluoride, calcium pyrophosphate abrasive placebo dentifrice
Number of subjects: 3093
Study: 29999570

Group type: EXPERIMENTAL
Intervention: Stained CAD/CAM materials (ENA, LVU, CER)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Polished CAD/CAM materials (CER, LVU, VM2, ENA)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Stained CAD/CAM materials after 5 years of aging (VM2, ENA, CER, LVU)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Stained CAD/CAM materials
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Aging effect on CAD/CAM materials (ENA, LVU)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Feldspathic ceramic (VM2)
Number of subjects: 15
Study: 30451047

Group type: EXPERIMENTAL
Intervention: Self-administration
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Face-to-face interview
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Postal questionnaire
Number of subjects: 66
Study: 27576596

Group type: EXPERIMENTAL
Intervention: Buprenorphine mixed with lignocaine 2% with adrenaline 1:80,000 (0.01mg buprenorphine/ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lignocaine 2% with adrenaline 1:80,000 + 0.03mg buprenorphine IM
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lignocaine 2% with adrenaline 1:80,000 + 1ml saline IM
Number of subjects: 60
Study: 24934008

Group type: EXPERIMENTAL
Intervention: Deep processing during study phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different study-test font and orientation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiovascular psychophysiological implicit priming paradigm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blood volume pulse change for words at study
Number of subjects: 0
Study: 23153715

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation as an add-on therapy for refractory epilepsy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 20338132

Group type: EXPERIMENTAL
Intervention: SFA stent placement
Number of subjects: 1282

Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 1282

Group type: EXPERIMENTAL
Intervention: SFA stent placement (secondary deployment)
Number of subjects: 1282

Group type: EXPERIMENTAL
Intervention: Combined primary and secondary SFA stents
Number of subjects: 1282
Study: 17103437

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy (1 mg/m²/day) for 2 years
Number of subjects: 25

Group type: COMPARATOR
Intervention: Growth hormone (GH) therapy (1.5 mg/m²/day) for 1 year after 1 year of observation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Observation without GH treatment for 1 year
Number of subjects: 25
Study: 14688492

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg daily)
Number of subjects: 10355

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10355
Study: 10670837

Group type: EXPERIMENTAL
Intervention: Alveolar macrophages from patients with ARDS
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control patients without lung injury
Number of subjects: 18
Study: 9088559

Group type: EXPERIMENTAL
Intervention: Viewer-centered (VC) condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Object-centered (OC) condition
Number of subjects: 0
Study: 8403822

Group type: EXPERIMENTAL
Intervention: Nottingham Health Profile (NHP)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Functional Limitations Profile (FLP)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Positive Well-being (PWB)
Number of subjects: 284
Study: 3777545

Group type: EXPERIMENTAL
Intervention: Anticoagulant treatment (heparin for 21 days followed by antivitamin K drugs for 30 days)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Acute hemodilution with 40,000 daltons molecular weight dextran, haematocrit 0.25-0.30, followed by the same anticoagulant treatment as in group I
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Only hemodilution maintained for 21 days
Number of subjects: 25
Study: 31326922

Group type: EXPERIMENTAL
Intervention: Supra-acetabular pin insertion
Number of subjects: 50
Study: 31629363

Group type: EXPERIMENTAL
Intervention: 12-week exercise program led by an accredited exercise physiologist (1 hr × 2 days/week × 12 weeks)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 12-week exercise program led by an accredited exercise physiologist
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 24
Study: 27866772

Group type: EXPERIMENTAL
Intervention: H1:IC31 vaccination (15μg or 50μg)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: H1:IC31 vaccination (15μg)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: H1:IC31 vaccination of M.tb-uninfected individuals
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: H1:IC31 vaccination of M.tb-infected individuals
Number of subjects: 240
Study: 26537160

Group type: EXPERIMENTAL
Intervention: Physiotherapy only (Group 1)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Acromioplasty and physiotherapy (Group 2)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Rotator cuff repair, acromioplasty, and physiotherapy (Group 3)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Physiotherapy only (Group 1) and Acromioplasty and physiotherapy (Group 2)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Rotator cuff repair and acromioplasty
Number of subjects: 180
Study: 23370547

Group type: EXPERIMENTAL
Intervention: Grading by site pathologist
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Grading by central pathologist
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Biopsies performed early (≤ 6 weeks) after transplant
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Grade A rejection
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Grade B rejection
Number of subjects: 481
Study: 22645791

Group type: EXPERIMENTAL
Intervention: Room temperature storage for 24 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Water storage at 37 degrees C for 24 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Onda-Cryl resin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: QC-20 resin
Number of subjects: 30
Study: 19318694

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 90 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 120 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg
Number of subjects: 42
Study: 17417133

Group type: EXPERIMENTAL
Intervention: Female Condom (FC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Male Condom (MC)
Number of subjects: 0
Study: 15293426

Group type: EXPERIMENTAL
Intervention: Dyract AP
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: F2000
Number of subjects: 33
Study: 11485110

Group type: EXPERIMENTAL
Intervention: Endotoxin (0.4 ng/kg) injected during sleep
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo injected during sleep
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Endotoxin (0.4 ng/kg) injected during sleep deprivation
Number of subjects: 20